BridgeBio Pharma Inc
BBIO
NASDAQ
Biotechnology
$79.86
USD
-1.35 (-1.66%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $15.84B
Volume 3.1M
Revenue
$713.07M
TTM
+202.4%
YoY
Gross Margin
94%
TTM
-1.8%
YoY
Net Income
$-702.02M
TTM
+10.6%
YoY
Operating Cash Flow
$-434.37M
TTM
+33.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 110.6 | 120.7 | 154.2 | 194.5 | 243.7 |
YoY Growth | +4999.9% | +4318.0% | +2521.2% | +66.8% | +120.4% |
Cost of Revenue | 3.7 | 6.6 | 8.1 | 9.9 | 15.0 |
Gross Profit | 106.9 | 114.1 | 146.1 | 184.6 | 228.6 |
Selling, General & Administrative | 129.2 | 137.6 | 158.1 | 163.9 | 186.3 |
Other Operating Expenses | 0.8 | 8.8 | 11.1 | 0.0 | 0.0 |
Total Operating Expenses | 241.2 | 259.3 | 285.6 | 290.5 | 335.7 |
Operating Income | -134.3 | -145.2 | -139.6 | -106.0 | -107.1 |
EBITDA | -132.2 | -135.0 | -127.0 | -104.8 | -106.0 |
Other Income / Expense | -39.7 | -35.8 | -47.9 | -53.9 | -42.2 |
Total Other Income / Expense | -47.4 | -41.3 | -55.2 | -60.6 | -48.8 |
Income Before Income Taxes | -181.7 | -186.5 | -194.8 | -166.6 | -155.9 |
Income Taxes | 2.1 | -1.5 | -0.1 | 0.0 | 0.0 |
Net Income | -183.8 | -184.9 | -194.6 | -166.6 | -155.9 |
Consolidated Net Income / Loss | -183.8 | -184.9 | -194.6 | -166.6 | -155.9 |
Net Income Attributable to Common Shareholders | -181.9 | -182.7 | -192.9 | -164.0 | -152.2 |
Basic EPS | -$0.95 | -$0.95 | -$1.00 | -$0.84 | -$0.78 |
Diluted EPS | -$0.95 | -$0.95 | -$1.00 | -$0.84 | -$0.78 |
Basic Shares Outstanding | 190.5M | 191.9M | 193.6M | 194.8M | 195.8M |
Diluted Shares Outstanding | 190.5M | 191.9M | 193.6M | 194.8M | 195.8M |